比较casirivimab和imdevimab、瑞德西韦和法匹拉韦在新冠肺炎住院患者中的疗效和安全性的临床研究

IF 1.6 Q4 INFECTIOUS DISEASES Journal of clinical virology plus Pub Date : 2023-06-01 DOI:10.1016/j.jcvp.2023.100151

Sahar K. Hegazy , Samar Tharwat , Ahmed H. Hassan

{"title":"比较casirivimab和imdevimab、瑞德西韦和法匹拉韦在新冠肺炎住院患者中的疗效和安全性的临床研究","authors":"Sahar K. Hegazy , Samar Tharwat , Ahmed H. Hassan","doi":"10.1016/j.jcvp.2023.100151","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Corona Virus disease - 2019 (COVID-19) disease induces scientific research to find a control to this pandemic from 2020 year up to now. Recently, various advances in pharmacotherapy against COVID-19 have emerged.</p></div><div><h3>Objectives</h3><p>To compare the efficacy and safety of antibodies cocktail (casirivimab and imdevimab), Remdesivir, and Favipravir in the COVID-19 patients</p></div><div><h3>Study design</h3><p>This study is a single-blind non-Randomized Controlled Trial (non-RCT). The drugs of the study are prescribed by lectures on chest diseases, faculty of medicine-Mansoura University. The duration of the study is about six months after ethical approval.</p><p>265 hospitalized COVID-19 patients were used to represent the COVID-19 population and were assigned into three groups in a ratio of (1:2:2) respectively, Group (A) received REGN3048–3051(Antibodies cocktail (casirivimab and imdevimab)), group (B) received remdesivir, and group (C) received favipravir.</p></div><div><h3>Results</h3><p>Casirivimab and imdevimab achieve less 28-day mortality rate, and less mortality at hospital discharge than Remdesivir, and Favipravir.</p></div><div><h3>Conclusion</h3><p>From all of these results, it is concluded that Group A (Casirivimab & imdevimab) achieves more favorable outcomes than B (Remdesivir) & C (Favipravir) intervention groups.</p></div><div><h3>Clinical trial registration</h3><p>NCT05502081, 16/08/2022, Clinicaltrials.gov</p></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"3 2","pages":"Article 100151"},"PeriodicalIF":1.6000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169321/pdf/","citationCount":"6","resultStr":"{\"title\":\"Clinical study to compare the efficacy and safety of casirivimab & imdevimab, remdesivir, and favipravir in hospitalized COVID-19 patients\",\"authors\":\"Sahar K. Hegazy , Samar Tharwat , Ahmed H. Hassan\",\"doi\":\"10.1016/j.jcvp.2023.100151\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Corona Virus disease - 2019 (COVID-19) disease induces scientific research to find a control to this pandemic from 2020 year up to now. Recently, various advances in pharmacotherapy against COVID-19 have emerged.</p></div><div><h3>Objectives</h3><p>To compare the efficacy and safety of antibodies cocktail (casirivimab and imdevimab), Remdesivir, and Favipravir in the COVID-19 patients</p></div><div><h3>Study design</h3><p>This study is a single-blind non-Randomized Controlled Trial (non-RCT). The drugs of the study are prescribed by lectures on chest diseases, faculty of medicine-Mansoura University. The duration of the study is about six months after ethical approval.</p><p>265 hospitalized COVID-19 patients were used to represent the COVID-19 population and were assigned into three groups in a ratio of (1:2:2) respectively, Group (A) received REGN3048–3051(Antibodies cocktail (casirivimab and imdevimab)), group (B) received remdesivir, and group (C) received favipravir.</p></div><div><h3>Results</h3><p>Casirivimab and imdevimab achieve less 28-day mortality rate, and less mortality at hospital discharge than Remdesivir, and Favipravir.</p></div><div><h3>Conclusion</h3><p>From all of these results, it is concluded that Group A (Casirivimab & imdevimab) achieves more favorable outcomes than B (Remdesivir) & C (Favipravir) intervention groups.</p></div><div><h3>Clinical trial registration</h3><p>NCT05502081, 16/08/2022, Clinicaltrials.gov</p></div>\",\"PeriodicalId\":73673,\"journal\":{\"name\":\"Journal of clinical virology plus\",\"volume\":\"3 2\",\"pages\":\"Article 100151\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169321/pdf/\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of clinical virology plus\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2667038023000182\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical virology plus","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667038023000182","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 6

摘要

背景2019冠状病毒病（新冠肺炎）导致科学研究从2020年到现在寻找对这一流行病的控制。最近，针对新冠肺炎的药物治疗取得了各种进展。目的比较抗体混合物（casirivimab和imdevimab）、Remdesivir和Favipravir在新冠肺炎患者中的疗效和安全性研究设计本研究是一项单盲非随机对照试验（非RCT）。这项研究的药物是由曼苏拉大学医学院关于胸部疾病的讲座开具的。该研究的持续时间约为伦理批准后6个月。265名住院新冠肺炎患者代表新冠肺炎人群，并分别按（1:2:2）的比例分为三组，（a）组接受REGN3048-3051（抗体混合物（casirivimab和imdevimab）），（B）组接受瑞德西韦，（C）组接受法韦。结果Casirivimab和imdevimab的28天死亡率和出院死亡率低于Remdesivir和Favipravir；C（Favipravir）干预组。临床试验注册NCT05502081，2022年8月16日，Clinicaltrials.gov

本文章由计算机程序翻译，如有差异，请以英文原文为准。

摘要图片

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Clinical study to compare the efficacy and safety of casirivimab & imdevimab, remdesivir, and favipravir in hospitalized COVID-19 patients

Background

Corona Virus disease - 2019 (COVID-19) disease induces scientific research to find a control to this pandemic from 2020 year up to now. Recently, various advances in pharmacotherapy against COVID-19 have emerged.

Objectives

To compare the efficacy and safety of antibodies cocktail (casirivimab and imdevimab), Remdesivir, and Favipravir in the COVID-19 patients

Study design

This study is a single-blind non-Randomized Controlled Trial (non-RCT). The drugs of the study are prescribed by lectures on chest diseases, faculty of medicine-Mansoura University. The duration of the study is about six months after ethical approval.

265 hospitalized COVID-19 patients were used to represent the COVID-19 population and were assigned into three groups in a ratio of (1:2:2) respectively, Group (A) received REGN3048–3051(Antibodies cocktail (casirivimab and imdevimab)), group (B) received remdesivir, and group (C) received favipravir.

Results

Casirivimab and imdevimab achieve less 28-day mortality rate, and less mortality at hospital discharge than Remdesivir, and Favipravir.

Conclusion

From all of these results, it is concluded that Group A (Casirivimab & imdevimab) achieves more favorable outcomes than B (Remdesivir) & C (Favipravir) intervention groups.